Investor Relations
Alseres Pharmaceuticals, Inc. (ALSE) is focused on the development of diagnostic and therapeutic products for disorders in the central nervous system (CNS). Our lead product candidate is Altropane®, a proprietary molecular imaging agent used to diagnose Parkinson's disease and dementia. Altropane is presently in Phase III clinical development for the diagnosis of Parkinson's disease. Our development strategy for Altropane anticipates entering into one or more partnerships to ensure development and commercialization of the product.
Stock Quote 02/03/12
- 1:12 PM ET
| ALSE | OT |
| Price: | $0.36 |
| Change: | - 0.02 |
| Quotes delayed at least 20 minutes. Information provided by eSignal. |
|
Featured Reports
| Form 10-Q Nov 10, 2011 |
 |
287.8 KB |
